Teva: Studies Show Efficacy Of Fremanezumab In Patients With Migraine And Major Depressive Disorder

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) reported the results of two studies, which demonstrated the efficacy of AJOVY or fremanezumab in migraine patients who also experience

Related Keywords

New York ,United States ,Hebron ,Israel General ,Israel ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Richard Lipton ,Dieter Schultewolter ,Patricia Pozo Rosich ,Department Of Neurology ,Hebron University Hospital ,Global Medical Affairs Neuroscience At Teva ,More Such Health News ,Hebron Institute Of Research ,Teva Pharmaceutical Industries Ltd ,Pharmaceutical Industries ,Behavioural Sciences ,Albert Einstein College ,Hebron Institute ,Vice President ,Global Medical Affairs Neuroscience ,Teva ,Studies ,Show ,Efficacy ,Remanezumab ,Patients ,Ith ,Migraine ,Major ,Depressive ,Disorder ,